Results 51 to 60 of about 15,859 (208)

[18F]FMCH PET/CT biomarkers and similarity analysis to refine the definition of oligometastatic prostate cancer

open access: yesEJNMMI Research, 2021
Background The role of image-derived biomarkers in recurrent oligometastatic Prostate Cancer (PCa) is unexplored. This paper aimed to evaluate [18F]FMCH PET/CT radiomic analysis in patients with recurrent PCa after primary radical therapy.
Martina Sollini   +10 more
doaj   +1 more source

Recommendations for radiation therapy in oligometastatic prostate cancer: An ESTRO-ACROP Delphi consensus [PDF]

open access: yes, 2022
BACKGROUND AND PURPOSE Oligometastatic prostate cancer is a new and emerging treatment field with only few prospective randomized studies published so far.
Zilli, Thomas   +4 more
core   +1 more source

Survival patterns after perioperative treatment escalation and cystectomy for synchronous oligometastatic bladder cancer (M1a/M1b) – a population-based series

open access: yesScandinavian Journal of Urology
Background: The role of cystectomy in synchronous oligometastatic bladder cancer is unclear. Objective: To describe a population-based consecutive cohort with primary oligometastatic bladder cancer (M1a or M1b) treated with curative intent.  Methods:
Fredrik Liedberg   +14 more
doaj   +1 more source

Perioperative FLOT chemotherapy plus surgery for oligometastatic esophagogastric adenocarcinoma: surgical outcome and overall survival

open access: yesBMC Surgery, 2021
Background Guidelines do not recommend surgery for patients with oligometastatic disease from esophagogastric adenocarcinoma (EGAC), although some studies suggest a more favorable survival.
Mira Runkel   +5 more
doaj   +1 more source

Stereotactic Prostate Cancer Ablative Re‐Irradiation: A Systematic Review and Meta‐Analysis (SPARE)

open access: yesThe Prostate, Volume 86, Issue 16, Page 1556-1568, Deceamber 2026.
ABSTRACT Background Stereotactic ablative radiotherapy (SABR) is emerging as an alternative treatment for patients with locally recurrent prostate cancer after previous radiation. This approach allows for precise target coverage while limiting toxicity to surrounding organs.
Andre G. Gouveia   +12 more
wiley   +1 more source

A phase II randomized trial of metastasis-directed therapy with alpha emitter radium-223 in men with oligometastatic castration-resistant prostate cancer (MEDAL)

open access: yesBMC Urology, 2023
Background The significance of metastasis-directed therapy for oligometastatic prostate cancer has been widely discussed, and targeted therapy for progressive sites is a feasible option as a multidisciplinary treatment for castration-resistant prostate ...
Soichiro Yoshida   +33 more
doaj   +1 more source

Total Neoadjuvant Treatment for Esophageal Adenocarcinoma With Oligometastases: TNT‐OES‐1 Trial

open access: yesInternational Journal of Cancer, Volume 159, Issue 10, Page 2552-2561, 15 November 2026.
Total neoadjuvant therapy could combine the potentially strong systemic effect of FLOT chemotherapy with the good locoregional control of CROSS chemoradiotherapy. While total neoadjuvant therapy is increasingly used in rectal cancer, its potential in gastroesophageal cancer remains largely unexplored.
Charlène J. van der Zijden   +12 more
wiley   +1 more source

Stereotactic ablative radiotherapy for oligometastatic breast cancer in elderly patients

open access: yes, 2020
Breast cancer (BC) is the principal cause of cancer-related death in women. Metastatic patients are usually treated with a systemic therapy, but clinical results are limited.
Lloret, Marta   +10 more
core   +1 more source

Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Lung Nodules: A Single Institution Series

open access: yesFrontiers in Oncology, 2019
Aim: Lung metastases from an extra-pulmonary origin occasionally present with a limited metastatic disease burden. In cases where metastatectomy is not feasible, stereotactic body radiation therapy (SBRT) represents a non-invasive, efficacious option. We
Rodney E. Wegner   +4 more
doaj   +1 more source

Stereotactic body radiotherapy for recurrent and oligometastatic soft tissue sarcoma

open access: yesWorld Journal of Surgical Oncology, 2022
Background Soft tissue sarcoma (STS) is a malignant tumor of highly heterogeneous mesenchymal origin. STS has a biological pattern and clinical transformation with localized invasive growth and is susceptible to hematogenous metastasis. Local therapeutic
Xiao-Yao Feng   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy